Longitudinal Multimodal Imaging in Mild to Moderate Alzheimer’s disease:
a Pilot Study with Memantine

Reinhold Schmidt, M.D.1,2, Stefan Ropele, Ph.D.1, Barbara Pendl, M.D.1, Petra Ofner, Ph.D.3, Christian Enzinger, M.D.1, Helena Schmidt Ph.D., M.D.4, Andrea Berghold, Ph.D.3, Manfred Windisch, Ph.D.5, Harald Kolassa, Ph.D.6, Franz Fazekas, M.D.1

1 Department of Neurology, 2 Divisions of Neuroradiology and Nuclear Medicine, Department of Radiology, 3 Institute for Medical Informatics, Statistics and Documentation, 4 Institute for Molecular Biology and Biochemistry, Medical University of Graz, Austria 5 JSW Research, Forschungslabor GmbH, Graz, Austria 6 Merz Pharma Austria GmbH, Vienna, Austria

Keywords: Alzheimer’s disease, treatment, memantine, MRI, PET, spectroscopy
Word count: 227 (abstract); 3599 (text excl. title page, references, figures and tables)
Running title: Longitudinal multimodal imaging in AD

Address for correspondence: Reinhold Schmidt, M.D.
Department of Neurology
Medical University of Graz
Auenbruggerplatz 22
A-8036 Graz, Austria
Phone: +43-316-385-83397
Fax: +43-316-32 55 20
e-mail: reinhold.schmidt@meduni-graz.at

1 (Schmidt R et al)
ABSTRACT

Objective: We studied the feasibility of multimodal neuroimaging in mild to moderate Alzheimer’s disease (AD) and estimated the size of possible treatment effects of memantine on potential functional, structural, and metabolic biomarkers of disease progression.

Methods: In this randomized, double-blind, placebo-controlled pilot study, 36 patients with moderate AD received 52 weeks of memantine (20mg/day) or placebo. Patients were re-evaluated after 26 and 52 weeks to measure the change from baseline in several outcome measures including global and regional glucose metabolism, total-brain and hippocampal volumes, as well as chemical shift imaging-derived global and regional N-acetylaspartate and myoinositol concentrations.

Results: In the total population, global glucose metabolism decreased by 2.3% (p<0.01), total-brain volume by 2.1% (p<0.0001), and hippocampal volume by 2.7% (p<0.01) after 52 weeks. Chemical shift imaging (CSI) spectra were severely affected by patient-induced artefacts and highly variable. Patients receiving memantine showed less decline in glucose metabolism in all brain areas than patients on placebo. Their loss of hippocampal volume was substantially smaller (2.4% vs. 4.0%). No between-group differences were seen for changes in total-brain volume.

Conclusions: Our results support the use of multimodal imaging including MRI and PET to monitor the progression of moderate AD. CSI yielded unreliable longitudinal results. Our data suggest that memantine has potentially protective effects in AD and they can be used for planning larger confirmatory studies on the cerebral effects of memantine.
INTRODUCTION

Current treatments in Alzheimer's disease (AD) apparently do not slow the disease.[1] Therapies that modify AD by interfering with the underlying neurodegeneration are under investigation.[2] Neuroimaging markers that substantiate disease-modifying effects are attractive investigational targets.[3, 4] The rate of whole-brain and hippocampal volume loss, longitudinal changes in N-acetylaspartate (NAA), choline, and myoinositol (MI) concentrations, and decline in brain perfusion and metabolism are potential imaging endpoints for therapeutic trials.[4] They reportedly correlate with the severity of histopathology[5-8] and cognitive performance.[4]

Few therapeutic trials have implemented these measures in AD patients and most of them used a single modality approach.[9-14] This provides a restricted view on disease-related changes over time and considers only selected aspects of treatment effects although these may be manifold, including brain metabolism, function, and structure. These different aspects may now be appreciated by specific imaging technologies, but the feasibility and contribution of long-term multimodal imaging to study therapeutic responses in AD has not yet been sufficiently explored. Knowledge of long-term change in different imaging measures and assessment of the variability of results in AD patients are a pre-requisite for the use of such methods in treatment-trials, as is reproducibility assessment. Such data could be obtained from a purely observational study unclouded by possible therapeutic effects. However, it is difficult to conduct long-term studies in AD patients without offering them any treatment. We, therefore, performed a one-year pilot feasibility study on multimodal imaging in mild to moderate AD coupled with specific treatment. We determined the longitudinal changes and their variability on 18F-FDG positron emission tomography (PET), chemical shift imaging (CSI), and 3D magnetic resonance imaging (MRI) in AD patients who had been randomized to receive either memantine or placebo.

PATIENTS AND METHODS

Patients
Patients over 50 years old were eligible if they had a diagnosis of probable AD according to the DSM-IV[15] and NINCDS-ADRDA criteria,[16] a Hachinski score ≤4,[17] and an MMSE score between 14 and 22.[18] When we started the study, cholinesterase inhibitors were approved in Austria for mild to moderate AD (MMSE 12-24), and memantine for moderately severe and severe AD (MMSE 3-14). We considered a placebo group to be crucial but did not want to exclude study participants from approved treatments. Therefore, we included only those patients who (1) had either failed to respond to cholinesterase inhibitors or experienced severe side effects leading to termination of such treatment, and (2) had MMSE scores >14 which, at the time of study conduct, had excluded them from other approved antidementia treatment once cholinesterase inhibitors had been stopped. To avoid withholding licensed therapy from study participants, we a priori defined that, whenever a participant worsened clinically obtaining an MMSE score <15, he/she would be switched to active treatment without breaking the double-blind code and remain in the study. This applied to three cases in the placebo group.

None of the patients included could obtain licensed treatment at study entry or would be withheld such treatment during the study which prompted the local ethics committee to
approve a one-year placebo-controlled trial. Cholinesterase inhibitor treatment had to be
terminated at least four weeks before screening. In addition, patients had to be in generally
good health, ambulatory, and with sufficient hearing and vision for compliance with testing
procedures. Only patients able to undergo MRI were enrolled. Patients with a primary
diagnosis of psychiatric disorders other than AD, cerebrovascular disease, or any unstable
medical condition were excluded. Patients were permitted to continue on stable doses of
concomitant medications received at least three months before screening. These included low-
dose atypical neuroleptics, selective serotonin re-uptake inhibitors, non-centrally active
antihypertensives, anti-inflammatory drugs, platelet antiaggregants and anticoagulants,
laxatives, diuretics, and sedatives/hypnotics. Anticonvulsants, anti-Parkinson agents,
barbiturates, Gingko biloba and nootropics, systemic corticosteroids and insulin were not
permitted.
The study was carried out according to the Declaration of Helsinki. Written informed consent
was obtained from both the patients and their caregivers.

Protocol
This was a single-centre, 52-week, randomized, double-blind, placebo-controlled, parallel-
group pilot study conducted at the Medical University of Graz, Austria, between March 2003
and August 2005. Patients were randomly assigned by a computerized randomization
schedule to either placebo or memantine. Randomization used a permuted block design and
considered the presence or absence of an apolipoprotein-E-ε4 allele as a stratification
criterion, because of previous data indicating more rapid decline in apolipoprotein-E-ε4
 carriers.[19] Briefly, two randomization lists were generated, one for all patients carrying at
least one apolipoprotein-E-ε4 allele and one for all other apolipoprotein-E genotypes, so that
carriers and non-carriers were equally distributed between the two treatment groups.
Patients assigned to memantine were titrated to a dose of 20mg/day over a four-week period.
Daily dose consisted of two identical tablets so as not to reveal the titration scheme: two
placebo tablets throughout the study for placebo patients and two tablets containing either
5mg or 10mg memantine depending on the titration stage for memantine-treated patients.
Evaluation of imaging data was blinded to the patients’ clinical results.
We screened patients by medical history, physical and neuropsychiatric examination,
laboratory assessment including apolipoprotein-E genotyping, MMSE,[18] Geriatric
Depression Scale,[20] and modified Hachinski scale.[17] All subjects had an ECG, and a
brain CT or MRI scan not older than one year. Screening was done within the 31 days before
patients began double-blind treatment and verification of AD diagnosis was based on
screening results. At baseline, we repeated the physical examination including vital signs,
MMSE, and laboratory. In addition, participants underwent psychometric testing including
Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog).[21] Clinical
Dementia Rating (CDR)[22], and Alzheimer’s Disease Cooperative Study – Activities of
Daily Living inventory (ADCS-ADL)[23], and MRI, quantitative ^1^H-CSI, and ^18^F-FDG PET.
The first dose of study medication was then administered. Follow-up visits were scheduled at
the end of weeks 12, 26, and 52. At each follow-up visit, routine physical examination,
laboratory, psychometric testing, medication compliance check, and adverse events
monitoring were done.
MRI and ^1^H-CSI were repeated at weeks 26 and 52; PET scanning was repeated at the end of
week 52, only. Patients who withdrew prematurely were requested to return for a final
evaluation identical to week 52.
Efficacy Assessments

The outcome variables were changes of total-brain and hippocampal volume, regional changes in NAA and MI in relation to baseline at weeks 26 and 52, as well as the global and regional changes of glucose metabolism between baseline and week 52.

\(^{18}\text{F} – \text{FDG Positron Emission Tomography (PET)}

PET scans were acquired on a Siemens-ECAT scanner (Siemens Medical Systems, Erlangen) 30 minutes after intravenous injection of 250MBq of \(^{18}\text{F}\)-FDG. Imaging was done in a resting condition with eyes open and ears unoccluded in a dark room with minimal ambient noise. Transmission scans were acquired before the emission scan for attenuation correction. The imaging plane was parallel to the cantho-meatal line. The spatial in-plane resolution was 4.5mm and axial resolution was 6mm full width at half maximum. Using a filtered back-projection method, all images were reconstructed in a 128x128x63 matrix providing a pixel size of 2.5x2.5x2.4mm.

MRI

The acquisition of structural scans and CSI was done in a single session on a 1.5T Philips-Intera scanner (Philips, Medical Systems, Best). The scan protocol included an axial FLAIR sequence (TR=6000ms;TE=130ms;TI=1200ms;FOV=230mm;matrix=256x256;THK=5mm), an axial T2-weighted fast-spin-echo (FSE) sequence (TR=3900ms;TE=80ms;FOV=230mm;matrix=256x256;THK=5mm), and a volumetric magnetization-prepared rapid gradient-echo (MPRAGE ) sequence (flip angle=15°;TR=20ms;TE=4.5ms;TI=400ms) with whole-brain coverage. To allow manual segmentation of the hippocampus, the MPRAGE sequence was acquired perpendicularly to the long axis of the hippocampus with a 1.0x1.0mm in-plane resolution and with 1.2mm-thick partitions. Additionally, for the CSF correction of the CSI data and for the regional analysis of the PET data, a T1-weighted true inversion-recovery (IR-) FSE sequence (TR=4400ms;TE=15ms;TI=350ms) with a high in-plane resolution (0.45x0.90mm) was performed in an axial orientation.

Quantitative \(^1\text{H} \text{chemical shift imaging (CSI)}

CSI was done in a single axial slice using a point-resolved spectroscopy sequence (PRESS) and a circularly polarized transmit-receive coil. The PRESS sequence was performed with TE=30ms, TR=1500ms, and a 24x24 acquisition matrix. The 15mm-thick slice had an in-plane resolution of 10x10mm and was positioned to match exactly the five central slices of the IR-FSE sequence. The PRESS sequence was performed slice-selectively instead of selecting a large volume of interest. This enabled full coverage of the parenchyma in the imaging slice but required multiple rest slabs to suppress unwanted fat signal from bone and skull. Water suppression was done with an adiabatic saturation pulse. Shimming and power optimization was done fully automated. To allow for eddy-current correction and improved phasing of the spectra, a water-unsuppressed reference scan with a reduced acquisition matrix (12x12) but otherwise identical parameters was performed prior to the water-suppressed scan. To obtain absolute metabolite concentrations, a calibration measurement with a spherical phantom containing 50mmol/L NAA and 100mmol/L phosphate was performed after each session. To correct for variation of the coil load between patients and the calibration phantom, the coil load for each measurement was determined during the power optimization process and recorded. The acquisition time for MRI and CSI without calibration was approximately 45min.

5 (Schmidt R et al)
Analysis of imaging data

Glucose metabolism
Regional glucose metabolism was measured manually in predefined regions of interest in the PET images including the frontal, parietal, occipital, and temporal lobe, and the basal ganglia. The relative counts obtained from these regions were normalized by the pons activity. Region outlining was done on the baseline IR-FSE scan, after the baseline and follow-up PET scan had been registered with it. Registration was done with an affine 9-parameter model following skull stripping of the IR-FSE scan. The region masks produced at baseline were also used for the analysis of the follow-up PET scans.

Brain volumes
Whole-brain atrophy and normalized brain volume (NBV) were calculated from the MPRAGE scan using the fully automated SIENA and SIENAX methods, respectively, which are part of the FSL (FMRIB’s software library: www.fmrib.ox.ac.uk/fsl). In addition to its robustness, SIENA provides an error in brain volume change of about 0.2%. SIENAX determines NBV by extraction of brain tissue, calculation of brain volume, and normalization for subject head size using a volumetric scaling factor. The scaling factor is obtained by an affine registration of the brain image to MNI152 space. The NBV was assessed at baseline only, while the measurement of brain volume change was done for all subsequent time points. Hippocampal volumes were measured from the T1-weighted MPRAGE scans. After image intensity normalization and registration with the baseline examination, manual tracing of the hippocampal formation was done on magnified and interpolated coronal sections. Manual tracing was done blinded to clinical information and time point of examination, in consultation with neuroanatomic atlases. The outlined volume included the hippocampus proper (cornu ammonis CA1 through CA4), gyrus dentatus, subiculum, uncal apex, fimbria and alveus, and excluded the entorhinal cortex (ambient gyrus, parahippocampal gyrus). The hippocampal volume was obtained by averaging the volume of the left and the right hippocampus.

Brain metabolites
CSI data were processed voxel-by-voxel by the fully automated method LCModel. LCModel analyzes an in vivo spectrum as a linear combination of model spectra of metabolite solutions in vitro and provides absolute quantification by reference to an external calibration standard. To account for differences in scanner characteristics between the acquisition of the metabolite solutions in vitro and the in vivo spectra, LCModel uses a calibration factor to scale the in vivo spectra. According to the methodological requirements, the calibration factor was obtained by using LCModel to estimate the known NAA concentration in the calibration phantom and by regarding differences in the coil load factor. Additionally, the low-resolution, unsuppressed CSI data were incorporated in the algorithm to facilitate phasing and eddy-current correction. NAA and MI maps showing the absolute metabolite concentrations were generated from the voxel-wise analysis. These maps were then overlaid on the central slices of the IR-FSE scan which were virtually aligned with the CSI data. No active registration of the IR-FSE scan and metabolite maps was done. Regional measurement of metabolite concentration was done by clustering individual voxels using home-written tools. Due to the high resolution and excellent T1-contrast, the IR-FSE scan also allowed to separate grey matter, white matter, and CSF in each spectroscopic voxel to correct for CSF occupancy. The
relative CSF occupancy was calculated by fitting three Gaussian functions into the signal intensity distribution function in each voxel.

**Statistical analyses**
This study was a first attempt to provide morphologic and functional imaging data on the action of memantine in AD in a complex multimodal manner, and was thus designed as a pilot study. All efficacy variables were analyzed in a descriptive and exploratory manner. P-values have to be interpreted accordingly, with no adjustments made for multiplicity. The analyses were done by intention-to-treat. Differences in percentage brain volume change and annual change of normalized glucose metabolism for the whole brain and predefined brain regions between the two groups were assessed using the unpaired t-test or Mann-Whitney U-test, as appropriate. Analysis was performed for changes from baseline to 6 and 12 months. A paired t-test or the Wilcoxon signed-rank test was used for the difference between baseline and final examination overall and within groups. For NAA or MI levels within regions of interest, analysis of covariance including treatment group as the main factor in the model and baseline as covariate was performed. The correlation between glucose metabolism and volumetric measures was determined with the Spearman rank-correlation coefficient.

**RESULTS**

Thirty-seven patients were randomized of which 36 (one had claustrophobia in the MR-scanner) received study medication (18 memantine and 18 placebo). Baseline characteristics of the study group are shown in Table 1. The two groups were comparable regarding age, gender, depression score, severity of cognitive symptoms, and normalized brain volume.

**Table 1. Baseline Characteristics of Patients with Alzheimer's Disease in a 52-Week, Randomized, Double-blind, Placebo-controlled Trial on the Effects of Memantine on Brain Morphology and Metabolism**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total Group (n=36)</th>
<th>Placebo (n=18)</th>
<th>Memantine (n=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>76.2 (5.21)</td>
<td>75.8 (5.70)</td>
<td>76.5 (4.81)</td>
</tr>
<tr>
<td>Sex, female</td>
<td>23 (63.9)</td>
<td>10 (55.6)</td>
<td>13 (72.2)</td>
</tr>
<tr>
<td>Apo-E-ε4 allele</td>
<td>16 (44.4)</td>
<td>8 (44.4)</td>
<td>8 (44.4)</td>
</tr>
<tr>
<td>Hachinski score</td>
<td>1.1 (1.27)</td>
<td>0.8 (0.99)</td>
<td>1.4 (1.46)</td>
</tr>
<tr>
<td>MMSE</td>
<td>19.0 (2.90)</td>
<td>19.3 (2.72)</td>
<td>18.7 (3.12)</td>
</tr>
<tr>
<td>GDS</td>
<td>2.4 (0.94)</td>
<td>2.2 (1.00)</td>
<td>2.6 (0.85)</td>
</tr>
<tr>
<td>CDR</td>
<td>1.6 (0.56)</td>
<td>1.5 (0.51)</td>
<td>1.6 (0.61)</td>
</tr>
<tr>
<td>ADAS-Cog</td>
<td>27.5 (10.59)</td>
<td>27.5 (10.00)</td>
<td>27.6 (11.45)</td>
</tr>
<tr>
<td>Normalized brain volume, mL</td>
<td>1298.3 (76.5)</td>
<td>1311.4 (77.5)</td>
<td>1285.9 (75.8)</td>
</tr>
</tbody>
</table>

* all variables are expressed as mean and standard deviation (SD) except for sex and APO-E-ε4 allele which are expressed as frequency and percentage.

MMSE = Mini Mental State Examination, GDS = Geriatric Depression Scale, CDR = Clinical Dementia Rating, ADAS-Cog = Alzheimer's Disease Assessment Scale – Cognitive Subscale
The 26-week follow-up was completed by 32 (89%) patients (16 in each group). Twenty-four (67%) participants (11 on placebo and 13 on memantine) finished the 52-week examination. Overall, 12 (7 placebo and 5 memantine) patients (33.3%) discontinued the study due to adverse events in 4, implantation of pacemaker in 3, technical MRI problems in 2, and non-compliance in 2 subjects. One patient died prior to the 52-week examination. All on memantine and 94% of patients on placebo received concomitant medication during the study. In the placebo and memantine group, 33% and 28% received low-dose neuroleptics, respectively; antidepressants were used in 39% and sedatives/hypnotics in 11% of patients in each group. Clinically, the total group was stable until week 26, and declined in all clinical assessments at week 52 (4.2 points on ADAS-Cog, 1.3 on MMSE, 0.4 on CDR, and 11 on ADCS-ADL). The 52-week decline in placebo patients on the ADAS-Cog, MMSE, CDR, and ADCS-ADL was 8.2, 2.0, 0.5, and 5.1 points, respectively. With 1.0, 0.7, 0.3, and 5.1 points, the clinical 52-week decline in memantine-treated study participants was slower.

After 52 weeks, the global decrease in cerebral glucose metabolism from baseline was 2.3% (SD:4.96%;p<0.01). Significant regional metabolic reductions were seen in the parietal (3.1%;SD:5.20%), basal ganglionic (2.7%;SD:6.00%), and temporal (2.3%;SD:4.01%) brain areas (p<0.01 each). Declines in the frontal (2.1%;SD:5.96%) and occipital (1.3%;SD:5.50%) areas were non-significant. Longitudinal co-registration of baseline and 52-week follow-up PET studies on MRI reference scans depicted the distribution of functional loss over time. Most AD cases showed a diffuse glucose metabolism decrease involving all brain areas, but some developed substantial asymmetric and focally confined reductions in brain metabolism over time (Figure 1 A-B). Memantine-treated subjects showed less annual decline in glucose metabolism in all brain areas compared to placebo (Figure 2). The differences were non-significant. In relative terms, the annual decline in global glucose metabolism in patients on memantine was 41% smaller than in those on placebo.

Table 2 shows the changes of MRI volumetric endpoints over time. There was a significant loss of total-brain (2.1%p.a.;p<0.0001) and hippocampal (2.7%p.a.;p<0.01) volumes in all patients. The annual reduction in total-brain volume was similar between the groups (2.0% placebo versus 2.3% memantine). At study end, patients on memantine showed 40.6% less hippocampal volume reduction than placebo patients (2.4% versus 4.0%).

**Table 2. Changes in MRI Volumetric Outcome Measures from Baseline in Patients with Alzheimer’s Disease in a 52-week, Randomized, Double-blind, Placebo-controlled Trial of the Effects of Memantine on Brain Morphology and Metabolism**

<table>
<thead>
<tr>
<th>Volumetry</th>
<th>Imaging Endpoint</th>
<th>Assessment</th>
<th>N</th>
<th>Total group</th>
<th>N</th>
<th>Placebo</th>
<th>N</th>
<th>Memantine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volumetry</td>
<td>Brain-volume change (%)</td>
<td>Week 26</td>
<td>29</td>
<td>-0.6 (1.69)</td>
<td>15</td>
<td>-0.8 (2.04)</td>
<td>14</td>
<td>-0.6 (1.23)</td>
</tr>
<tr>
<td>Volumetry</td>
<td>Hipocampal volume change (%)</td>
<td>Week 52</td>
<td>21</td>
<td>-2.1 (2.01)</td>
<td>12</td>
<td>-2.0 (1.92)</td>
<td>9</td>
<td>-2.3 (2.22)</td>
</tr>
<tr>
<td>Volumetry</td>
<td>Hipocampal volume change (%)</td>
<td>Week 26</td>
<td>29</td>
<td>-1.9 (2.82)</td>
<td>15</td>
<td>-2.4 (2.01)</td>
<td>14</td>
<td>-2.0 (2.70)</td>
</tr>
<tr>
<td>Volumetry</td>
<td>Hipocampal volume change (%)</td>
<td>Week 52</td>
<td>21</td>
<td>-2.7 (3.64)</td>
<td>12</td>
<td>-4.0 (3.99)</td>
<td>9</td>
<td>-4.2 (2.81)</td>
</tr>
</tbody>
</table>

Numbers are means (SD).
Differences between treatment groups were non-significant based on analysis of covariance (ANCOVA).
There existed no significant relationship between global change in glucose metabolism, and percentage change in total-brain ($r=-0.02$) and hippocampal ($r=-0.28$) volume. Even in the case with almost complete regional drop in glucose metabolism, only minimal sulcal widening was seen at the affected site during the 52-week observational period (Figure 1C-D).

CSI was severely affected by patient-induced artefacts, mostly due to patient motion during the 20-minute acquisition time. Motion resulted in incomplete fat saturation and marked line-width broadening in most cases. Depending on the brain region, many spectra were excluded from analysis due to unacceptable quality; this decision was made before unblinding. The exclusion rate was lowest in the parietal (5 cases) and highest in the occipital (19 cases) brain area. Analysis of the remaining spectra still yielded a high intra- and inter-individual variability of all metabolites with no clear trends over time for both the entire cohort and patient subgroups (data not shown).

**DISCUSSION**

We demonstrated that multimodal functional and morphologic neuroimaging is feasible in a treatment trial of patients with moderate AD. This 52-week study yielded significant reductions in glucose metabolism, and total-brain and hippocampal volumes in a group of AD patients with significant clinical deterioration. Our placebo patients showed similar cognitive decline to that reported in large-scale clinical AD trials,[30] and their annual 2.0%-loss of total-brain volume and 4.0%-loss of hippocampal volume are also consistent with previous reports,[31-34] which supports the validity of our study.

The greatest problems were posed by CSI. It is important to note here that there was a tremendous difference between single-voxel MRS and CSI regarding motion sensitivity. Obviously, a 20-minute acquisition time required per our quantitative CSI protocol was too long for many study participants. In patients who remained still in the scanner, CSI was technically feasible, but oftentimes data quality was severely degraded by patient-induced motion artefacts. Typically, head motion resulted in line-width broadening and displacement errors leading to a high rate of spectra of unacceptable quality and to highly variable metabolite concentrations. Thus, low patient compliance can clearly be a major limiting factor when using CSI in longitudinal dementia studies.

Recent developments such as turbo CSI or the incorporation of the SENSE technique reduces acquisition time and may overcome some of the problems we encountered. Until respective studies are available, single-voxel spectroscopy with substantially shorter acquisition times may be preferable in demented patient populations.

We saw no, or at most poor, correlations between metabolic and volumetric cerebral changes over time. Even in the case with almost complete focal loss of metabolic activity in the right temporal-parietal area, sulcal widening was barely present. This suggests long-term latency between functional deterioration and cellular loss in AD, a finding corroborated by studies in presymptomatic familial AD individuals who also showed widespread reductions in glucose metabolism in the relative absence of structural brain changes long before the clinical onset of the disease.[35]

This is also the first investigation utilizing neuroimaging techniques to study treatment effects of memantine. Memantine preferentially blocks excessive NMDA-receptor activity without disrupting normal receptor activity and is thought to be a neuroprotective agent that attenuates excitotoxicity. Various experiments on cellular and tissue level as well as in animal models
Support this assumption.[36] Selection of imaging methods for the current study attempted to cover possible treatment-related effects as comprehensively as possible. Slowing of decline in glucose metabolism and of hippocampal volume loss seen in memantine-treated patients compared to those on placebo is in favour of functional and neuroprotective effects of this substance. However, caution is advised when interpreting these findings, because our study was not powered to detect statistically significant results and we could be dealing with spurious findings. It is important to emphasize that this study was conducted to facilitate planning of larger confirmatory trials. Nevertheless, glucose metabolism in memantine-treated patients was preserved longer in all brain areas, and the effects on PET results and on hippocampal volume were substantial (PET global annual change: 1.8% in memantine-treated versus 3% in placebo patients; hippocampal volume annual percentage change: 2.4% in memantine-treated versus 4% in placebo patients). In relative terms, global cerebral glucose utilization and hippocampal volume showed a non-significant trend towards a 40% lower annual decline in the memantine than in the placebo group. This result can serve for rough orientation on sample sizes needed. Based on memantine’s one-year effect on global glucose metabolism and hippocampal volume, the sample sizes required to detect this 40%-reduction in a one-year trial with a power of 80% (two-sided t-test at 5%-level) are 202 and 70 patients per group, respectively.

The use of multimodal imaging in this study suggests that memantine has functional effects in all brain regions affected by AD while the substance exerted morphological effects only on the hippocampus but not on the whole brain. We can certainly not exclude that global effects on brain volume may be seen with observation times exceeding one year. Hypotheses explaining slower hippocampal degeneration in the absence of effects on total-brain volume are difficult to formulate as the mechanisms of neuronal loss in AD are largely unknown. Possibly, the hippocampus may be particularly involved in mild to moderate AD stages studied in the current trial. Another explanation is that memantine exerts more pronounced activity on the hippocampus than on other brain regions because the hippocampus contains a high density of NMDA-receptors, particularly in the CA1 area.

In conclusion, the data of this pilot study show that multimodal neuroimaging is feasible in a patient population with mild to moderate AD, and consistent changes over time can be detected by all methods except CSI. Our data suggest that memantine slows the decline in glucose metabolism and slows the progression of hippocampal atrophy supporting its potential disease-modifying effect in AD. Larger trials including PET scanning and hippocampal measurements are warranted to confirm these results.

10 (Schmidt R et al)
FIGURE LEGENDS

Figure 1 A-D
Baseline (A) and 52-week (B) PET scans registered on MRI in an 85-year-old female study participant who experienced a focal, almost complete loss of glucose utilization in the right temporo-parietal region. Glucose metabolism in other brain regions remained almost unchanged from baseline. The baseline scan demonstrated the typical symmetric temporo-parietal hypometabolism of patients with Alzheimer’s disease. The co-registered T1-weighted MRI scans show little, if any, sulcal enlargement in the area of metabolic loss in this patient between baseline (C) and follow-up (D).

Figure 2
Regional and global changes from baseline in glucose metabolism in patients with Alzheimer’s disease in a 52-week randomized, double-blind, placebo-controlled trial. Numbers below regions indicate the percentage decline in patients receiving memantine versus those receiving placebo. After 52 weeks, memantine-treated subjects had smaller reductions in all brain regions and globally. Differences did not reach statistical significance in this pilot study.

Statements on the conflict of interest
Reinhold Schmidt, M.D., has received compensation for lectures, consulting fees, and research funding from the sponsor of the reported study.
Manfred Windisch, Ph.D., has received consulting fees and research funding, and acted on behalf of the sponsor of the reported study.
Harald Kolassa, Ph.D., was a general manager at Merz Pharma Austria GmbH acting as sponsor of the reported study.
Franz Fazekas, M.D., has received consulting fees, reimbursement, and research funding (including funds for a staff member) from the sponsor of the reported study.

Statement from authors
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in JNNP and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://jnnp.bmj.com/ifora/licence.pdf).
REFERENCES

Figure 1 A-D

A

B

C

D
Figure 2

[Graph showing changes in glucose metabolism across different brain regions for Mamantine and Placebo groups.]
Longitudinal multimodal imaging in mild to moderate Alzheimer’s disease: a pilot study with memantine

Reinhold Schmidt, Stefan Ropele, Barbara Pendl, Petra Ofner, Christian Enzinger, Helena Schmidt, Andrea Berghold, Manfred Windisch, Harald Kolassa and Franz Fazekas

J Neurol Neurosurg Psychiatry published online June 27, 2008

Updated information and services can be found at:
http://jnnp.bmj.com/content/early/2008/06/27/jnnp.2007.141648

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Dementia (1020)
- Drugs: CNS (not psychiatric) (1945)
- Memory disorders (psychiatry) (1390)
- Psychiatry of old age (338)
- Radiology (1747)
- Radiology (diagnostics) (1309)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/